Continuous Adductor Canal Block

PreclinicalSmall molecule

MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Continuous Adductor Canal Block is one of 22 small molecule programs targeting Total Knee Arthroplasty. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Knee ArthroplastyActive, not recruiting

Total Knee ArthroplastyPreclinical

Active, not recruiting

Competition

Competitive Landscape

275 competitors in Total Knee Arthroplasty

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Preclinical

5 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 3

EXPAREL

Pacira Pharmaceuticals, Inc

Preclinical

7 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

2 5

Nucynta

CCollegium Pharmaceutical, Inc.

Preclinical

2 6

Epsom Salt

FFresenius Kabi Oncology Ltd.

Preclinical

1 7

Zanaflex

LLegacy Health System

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Iron Sulphate

PPierre Fabre Pharma GmbH

Preclinical

1 10

Bupivacain

IIstanbul University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adductor Canal Block1 trial

Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT02680392·40 enrolled

Total Knee Arthroplasty1 trial

Continuous Adductor Canal Block in Outpatient Total Knee Arthroplasty

Active, not recruiting·UUniversity of Toronto·N/A·NCT05100706·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Continuous Adductor Canal Block. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Continuous Adductor Canal Block compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Continuous Adductor Canal Block. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McGill University Health Centre/Research Institute of the McGill University Health Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Continuous Adductor Canal Block

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adductor Canal Block1 trial

Total Knee Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News